following a full submission:
nivolumab (Opdivo®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the adjuvant treatment of adult patients with completely resected oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.
In one randomised, double-blind, phase III study, nivolumab significantly improved disease-free survival compared with placebo in patients with oesophageal or gastro-oesophageal junction cancer who had complete resection and residual pathologic disease after neoadjuvant chemoradiotherapy.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Medicine details
- Medicine name:
- nivolumab (Opdivo)
- SMC ID:
- SMC2429
- Indication:
As monotherapy is indicated for the adjuvant treatment of adult patients with completely resected oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 May 2022